Summit, N.J. – Intervet/Schering-Plough Animal Health is
reintroducing to the United States market the Vista vaccine line, which provides dairy veterinarians and producers with the most complete protection available against the most common and costly bovine respiratory and reproductive diseases.
Vista vaccines protect dairy cattle against Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea (BVD Type 1 and Type 2), Parainfluenza3 (PI3), Bovine Respiratory Syncytial Virus (BRSV), leptospirosis, vibriosis, Mannheimia haemolytica and Pasteurella multocida.
The Vista line of vaccines was introduced to the market in 2005 with more research supporting its safety and efficacy than any other cattle vaccine at the time. A stop sale was issued on the vaccine in 2009 due to a variability issue with the BRSV antigen. Intervet/Schering-Plough Animal Health worked with the U.S. Department of Agriculture to resolve the issue and is pleased to welcome back this cattle vaccine to its portfolio and the market with even more research that confirms its superior respiratory and reproductive disease protection.
“Intervet/Schering-Plough Animal Health is committed to providing innovative, high-quality animal-health products that dairy veterinarians and producers trust,” says Ron Bryant, who leads the U.S. non-confined beef and dairy cattle business for Intervet/Schering-Plough Animal Health. “We are excited to welcome back Vista to our portfolio of products, are committed to being a reliable supplier and are confident Vista will deliver the protection needed to keep dairy animals healthy and productive.”
Vista vaccines are available through veterinarians and animal-health suppliers. For more on Vista’s respiratory protection, avirulent-live advantages, reproductive protection, complete fetal protection and lack of impact on milk production, as well as a list of presentations in which Vista vaccines are available, call customer service at 1-800-521-5767 or visit www.intervet.com.
